Tomoyuki Makino1, Hiroyuki Konaka2, Mikio Namiki2. 1. Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan mackeeen511@gmail.com. 2. Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
Abstract
BACKGROUND: The prognosis for non-seminomatous extragonadal germ cell tumors (EGCTs), especially mediastinal, has been shown to be worse than for seminomatous EGCTs. PATIENTS AND METHODS: Fourteen patients with EGCT (seven pure seminomas and seven non-seminomas) were treated at the Kanazawa University Hospital between 1992 and 2014; the primary tumor sites were mediastinum in nine patients and retroperitoneum in five patients. All patients were treated with cisplatin-based combination chemotherapeutic regimens followed by a multimodal strategy that included high-dose chemotherapy (HDCT), aggressive surgery, and early salvage chemotherapy. RESULTS: Although all patients with seminomatous EGCT achieved long-term survival, almost all patients with non-seminomatous EGCT had elevated serum tumor markers and high mortality rates. However, we experienced that patients with mediastinal non-seminomatous EGCT achieved long-term cancer-free survival with HDCT. The 5-year overall survival of patients with seminomatous and non-seminomatous EGCT was 100% and 44%, respectively. CONCLUSION: Herein we describe the treatment outcomes of patients with EGCT at our Institute and propose HDCT reconsideration for poor-risk patients. Copyright
BACKGROUND: The prognosis for non-seminomatous extragonadal germ cell tumors (EGCTs), especially mediastinal, has been shown to be worse than for seminomatousEGCTs. PATIENTS AND METHODS: Fourteen patients with EGCT (seven pure seminomas and seven non-seminomas) were treated at the Kanazawa University Hospital between 1992 and 2014; the primary tumor sites were mediastinum in nine patients and retroperitoneum in five patients. All patients were treated with cisplatin-based combination chemotherapeutic regimens followed by a multimodal strategy that included high-dose chemotherapy (HDCT), aggressive surgery, and early salvage chemotherapy. RESULTS: Although all patients with seminomatousEGCT achieved long-term survival, almost all patients with non-seminomatousEGCT had elevated serum tumor markers and high mortality rates. However, we experienced that patients with mediastinal non-seminomatousEGCT achieved long-term cancer-free survival with HDCT. The 5-year overall survival of patients with seminomatous and non-seminomatousEGCT was 100% and 44%, respectively. CONCLUSION: Herein we describe the treatment outcomes of patients with EGCT at our Institute and propose HDCT reconsideration for poor-risk patients. Copyright
Authors: J Aparicio; J Terrasa; I Durán; J R Germà-Lluch; R Gironés; E González-Billalabeitia; J Gumà; P Maroto; A Pinto; X García-Del-Muro Journal: Clin Transl Oncol Date: 2016-11-04 Impact factor: 3.405